Triple-positive profile may flag adverse prostate cancer pathology
-
By
-
Andrea Surnit
-
September 8, 2026
-
4 min
By
Andrea Surnit
September 8, 2026
by Andrea Surnit
September 8, 2026
Molecular testing may help avoid overtreatment when benign soft-tissue tumors present with atypical clinical or histologic features.
May 11, 2026
Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer, and mortality across three large cohorts.
June 18, 2026
Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.
September 1, 2026